Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Treatment Considerations and Sequencing in Multiple Myeloma

February 19th 2024

The expert panel concludes their discussion with clinical insights on treatment sequencing and therapeutic decision-making for patients who have relapsed.

CAR T-Cell Therapy in Multiple Myeloma: Role in the Treatment Landscape

February 19th 2024

A roundtable discussion on the evolving treatment landscape surrounding CAR T-cell therapy in multiple myeloma, with a focus on future directions and the management of adverse events.

Dr Baz on the Incidence of AEs With Ide-Cel in Triple-Class–Exposed Multiple Myeloma

February 16th 2024

Rachid Baz, MD, discusses findings from an analysis of cytopenias and infections in patients with multiple myeloma enrolled in the KarMMa-3 trial.

Dr Mikhael on Research Developments in Multiple Myeloma

February 15th 2024

Joseph Mikhael, MD, discusses treatment advancements and ongoing research in multiple myeloma.

Dr Parrondo on the RedirecTT-1 Trial of Teclistamab Plus Talquetamab in Multiple Myeloma

February 14th 2024

Ricardo D. Parrondo, MD, discusses the phase 1b/2 RedirecTT-1 of teclistamab and talquetamab in relapsed/refractory multiple myeloma.

Dr Zonder on Unmet Needs to be Addressed in Multiple Myeloma

February 13th 2024

Jeffrey Zonder, MD, discusses notable unmet needs that remain to be addressed in the treatment of patients with relapsed/refractory multiple myeloma.

GPRC5D-Targeting Bispecifics in Multiple Myeloma

February 12th 2024

The expert panel discusses recent clinical trial data on GPRC5D-targeting bispecific antibodies and how they apply to the multiple myeloma treatment paradigms.

Adverse Effects Related to Bispecifics in Multiple Myeloma

February 12th 2024

Comprehensive insights on the adverse effects seen from bispecific antibodies in the treatment of patients with multiple myeloma.

Data From 2023 ASH Annual Meeting Provide Positive Updates in Multiple Myeloma

February 11th 2024

Experts discuss treatment in newly diagnosed multiple myeloma and the role of CAR T-cell therapies and bispecifics in relapsed/refractory disease.

Dr Dima on the Mechanism of Action of Teclistamab in Relapsed/Refractory Multiple Myeloma

February 9th 2024

Danai Dima, MD, discusses the mechanism of action of teclistamab and why real-world outcomes with the agent were evaluated in a retrospective study.

Dr Siegel on the Rationale for Investigating KID in Multiple Myeloma

February 8th 2024

David Samuel Dicapua Siegel, MD, discusses a trial of carfilzomib, iberdomide, and dexamethasone in newly diagnosed, transplant-eligible multiple myeloma.

Retrospective Review Sheds Light on Real-World Efficacy With Teclistamab in R/R Myeloma After BCMA-Directed Therapy

February 8th 2024

Teclistamab produced responses in real-world patients with relapsed and refractory multiple myeloma and prior exposure to BCMA-targeted therapy.

Dr Parrondo on the Investigation of GPRC5D-Targeted CAR T-Cell Therapy in Multiple Myeloma

February 7th 2024

Ricardo D. Parrondo, MD, discusses the exploration of the non-BCMA CAR T-cell target GPRC5D in multiple myeloma.

Belantamab Mafodotin Plus Vd More Than Doubles PFS in Relapsed/Refractory Multiple Myeloma

February 6th 2024

Belantamab mafodotin plus bortezomib and dexamethasone improved PFS vs daratumumab plus bortezomib and dexamethasone in relapsed/refractory myeloma.

Dr Mikhael on the Importance of Disparities Research in Multiple Myeloma

February 6th 2024

Joseph Mikhael, MD, discusses the importance of researching disparities in treatment outcomes for patients with multiple myeloma.

Step-Up Dosing Practices for Bispecifics in Multiple Myeloma

February 5th 2024

Multiple myeloma specialists compare step-up dosing practices and provide clinical insights on treating patients with multiple myeloma.

Real-World Evidence and Selecting Optimal Bispecifics in Multiple Myeloma

February 5th 2024

Experts on multiple myeloma discuss how real-world evidence informs treatment selection for patients receiving bispecific antibodies.

Dr Mikhael on Unmet Needs in Cancer Care for Patients With Multiple Myeloma

February 4th 2024

Joseph Mikhael, MD, discusses the importance of closing gaps in care for patients with multiple myeloma in underserved populations.

Linvoseltamab Continues to Elicit Durable Efficacy in High-Risk Relapsed/Refractory Multiple Myeloma

February 3rd 2024

Hans Lee, MD, discusses updated data from the LINKER-MM1 study in heavily pretreated relapsed/refractory multiple myeloma.

EMA Accepts Marketing Authorization Application for Linvoseltamab in R/R Multiple Myeloma

February 2nd 2024

The EMA has accepted for review an MAA seeking the approval of linvoseltamab for use in select patients with relapsed/refractory multiple myeloma.